Liquidia Corporation (LQDA) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, LQDA scores 36 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 9 / 20. The rating cites ROIC of -12.6% and an FCF yield of -0.99%. For a prospective investor, this means the business is not currently generating returns on invested capital or free cash flow that would support the share price on fundamentals alone; valuation must rest on expectations of future earnings power rather than present cash generation.
• Whale 13F Flow: 7 / 20. The rating characterizes institutional accumulation and options positioning as weak. The investor implication is that large holders are not providing a strong demand tailwind, which leaves the stock more sensitive to retail or event-driven flows.
• Insider Conviction: 6 / 20. Per the rating, SEC Form 4 and Congressional PTR cluster flow is weak. Limited insider buying is not a direct negative signal on its own, but it removes one potential source of confidence for an outside investor.
• Macro Regime Fit: 3 / 20. The rating cites a beta of 0.9 and sector sensitivity. A beta near 0.9 suggests moves roughly in line with the broader market, but the low pillar score indicates the current regime is not favorable to the name's profile.
• Forensic Balance Sheet: 11 / 20. The rating cites an Altman Z-Score of 6.33, a Piotroski F-Score of 5/9, and a Debt/Equity ratio of 2.66. The high Z-Score points to lower near-term bankruptcy risk, while the leverage ratio and middling F-Score are the balance-sheet items a prospective investor should weigh most carefully.

Valuation tradeoff: with forward P/E of 21 and trailing EPS of -0.77, the stock is priced on forward expectations rather than reported earnings. The upside case depends on that forward earnings path materializing; the downside case is that it does not, and the shares have shown wide volatility, with a 52-week range of $22.21 - $93.61.

Per the market data, operating margin is -32.5%, net margin is -43.5%, gross margin is 0%, and ROIC is -12.6%. Per the Roarable RQD rating, the Altman Z-Score is 6.33 and the Piotroski F-Score is 5/9, with Debt/Equity at 2.66. Revenue rose substantially in FY 2025 to $158.3M from $14.0M in FY 2024, yet the company remained loss-making at the net income line. Debt was $518.3M in FY 2023 and $127.4M in FY 2025, while reported cash was $190.7M in FY 2025.

• Litigation settlement (GREEN catalyst): Multiple wire items report a $380.7M litigation settlement with United Therapeutics (UTHR), with the stock moving sharply higher on the news. Per the news feed, shares surged roughly 40–42% in reported coverage.
• Analyst target raise (GREEN catalyst): A TradingView item reports a 12-month price target raised to $53.5, which the headline states implies 100% upside.
• Earnings expectation coverage (YELLOW): A Yahoo Finance item discusses expected earnings growth.
• Investigation notice (YELLOW risk watch): Notices from a law firm regarding a pending investor investigation into LQDA were reported. The source data does not describe the substance of the investigation.
• Butterfly Supply-Chain Graph: Supply chain is listed as NONE, with no butterfly links and no proprietary signals. Not available in source data for supply-chain dependencies.

• What is the composition and timing of the $380.7M litigation settlement with United Therapeutics, and how much of it is cash versus other consideration?
• What products or revenue streams produced the jump from $14.0M in FY 2024 to $158.3M in FY 2025, and are they recurring?
• What is the nature of the pending investor investigation referenced in the law-firm notices?
• What drives the gap between reported net losses and the forward P/E of 21, and what earnings path does the forward estimate assume?
• What are the debt maturities and covenants behind the $127.4M debt balance, given the Debt/Equity ratio of 2.66?